ResearcherUniversity of GenoaActive in the last 2 years
Alessio Nencioni
Matched on ORCID iD 0000-0001-5068-8884; OpenAlex author ID A5006211032. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 15
2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper
Papers 6
- New Analogues of the Nicotinamide Phosphoribosyltransferase Inhibitor FK866 as Potential Anti-Pancreatic Cancer Agents. Co-author DOI 10.2174/0115734064289584240121142405↗
- Iminosugar-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Potential Anti-Pancreatic Cancer Agents. Co-author DOI 10.3390/pharmaceutics15051472↗
- Identification of new FK866 analogues with potent anticancer activity against pancreatic cancer. Last author DOI 10.1016/j.ejmech.2022.114504↗
- Induction of cell killing and autophagy by amphiphilic pyrrolidine derivatives on human pancreatic cancer cells. Co-author DOI 10.1016/j.ejmech.2018.02.086↗
- The GSK3β inhibitor BIS I reverts YAP-dependent EMT signature in PDAC cell lines by decreasing SMADs expression level. Co-author DOI 10.18632/oncotarget.8437↗
- The NAD+-dependent histone deacetylase SIRT6 promotes cytokine production and migration in pancreatic cancer cells by regulating Ca2+ responses. Last author DOI 10.1074/jbc.m112.405837↗
Closest collaborators
The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Irene Conforti · 2 shared papers, 2023–2024 · strength 0.48
- Paper New Analogues of the Nicotinamide Phosphoribosyltransferase Inhibitor FK866 as Potential Anti-Pancreatic Cancer Agents. DOI 10.2174/0115734064289584240121142405↗
- Paper Iminosugar-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Potential Anti-Pancreatic Cancer Agents. DOI 10.3390/pharmaceutics15051472↗
- Alberto Marra · 2 shared papers, 2023–2024 · strength 0.48
- Paper New Analogues of the Nicotinamide Phosphoribosyltransferase Inhibitor FK866 as Potential Anti-Pancreatic Cancer Agents. DOI 10.2174/0115734064289584240121142405↗
- Paper Iminosugar-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Potential Anti-Pancreatic Cancer Agents. DOI 10.3390/pharmaceutics15051472↗
- Faustino Mollinedo · 2 shared papers, 2018–2022 · strength 0.19
- Pierre Vogel · 2 shared papers, 2018–2022 · strength 0.19
- Jian‐Fei Bai · 2 shared papers, 2018–2022 · strength 0.19
- Consuelo Gajate · 2 shared papers, 2018–2022 · strength 0.19
- Aimable Nahimana · 2 shared papers, 2018–2022 · strength 0.19
- Sophie Poty · 1 shared paper, 2022 · strength 0.12
- Inga Bauer · 2 shared papers, 2012–2016 · strength 0.08
- Paper The GSK3β inhibitor BIS I reverts YAP-dependent EMT signature in PDAC cell lines by decreasing SMADs expression level. DOI 10.18632/oncotarget.8437↗
- Paper The NAD+-dependent histone deacetylase SIRT6 promotes cytokine production and migration in pancreatic cancer cells by r… DOI 10.1074/jbc.m112.405837↗
- Georg Feldmann · 2 shared papers, 2012–2016 · strength 0.08
- Paper The GSK3β inhibitor BIS I reverts YAP-dependent EMT signature in PDAC cell lines by decreasing SMADs expression level. DOI 10.18632/oncotarget.8437↗
- Paper The NAD+-dependent histone deacetylase SIRT6 promotes cytokine production and migration in pancreatic cancer cells by r… DOI 10.1074/jbc.m112.405837↗
- Caroline S. Breton · 1 shared paper, 2018 · strength 0.07
- Claudia Bello · 1 shared paper, 2018 · strength 0.07
- Natthakan Thongon · 1 shared paper, 2016 · strength 0.05
- Alessandro Provenzani · 1 shared paper, 2016 · strength 0.05
- Raul Mostoslavsky · 1 shared paper, 2012 · strength 0.02
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.